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HAIR-AN syndrome (hyperandrogenism, insulin resistance, acanthosis nigricans) is a 
subset of the polycystic ovary syndrome, where the patients demonstrate severe insulin 
resistance. It is theorized that both genetic and environmental factors, such as obesity, 
give rise to the development of HAIR-AN. Diagnosis is primarily clinical, with laboratory 
values lending further support. Treatment is aimed at decreasing insulin resistance, 
regulating ovulation, and decreasing acne, acanthosis nigricans, and hirsutism.  
KEYWORDS: hyperandrogenism, acanthosis nigricans, insulin resistance, United States 
 
INTRODUCTION  
HAIR-AN syndrome, which is characterized by hyperandrogenism, insulin resistance, and acanthosis 
nigricans, is a subphenotype of the polycystic ovary syndrome. This review will discuss the clinical 
presentation, genetic and environmental contributors, diagnosis, and interventions for treatment of this 
syndrome. 
BACKGROUND  
The polycystic ovary syndrome (PCOS) is a disease of infrequent or absent ovulation and 
hyperandrogenism. HAIR-AN syndrome is a specific subtype of PCOS characterized by the presence of 
severe insulin resistance[1,2]. Approximately 5–10% of females with hyperandrogenism have HAIR-
AN[3,4] and up to 40% of adolescent patients who present with irregular periods may have HAIR-AN[5]. 
Most women with HAIR-AN will have clinical symptoms in adolescence; however, diagnosis is often 
delayed until adulthood[6,7].  
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Clinical Presentation 
Clinically, hyperandrogenism associated with HAIR-AN may give rise to acne and slowly progressive 
hirsutism. Virilization, which includes temporal balding, voice deepening, rapidly progressive hirsutism, 
and clitoromegaly generally suggest more significant androgen exposure and warrant further 
evaluation[1,3]. Hirsutism is defined by an increase in the distribution and quantity of terminal hairs (>0.5 
cm in length, coarse, usually pigmented) representing a Ferriman and Gallwey score of ≥8[8]. 
Clinical findings related to insulin resistance are body mass index (BMI) >27 kg/m2, waist to hip ratio 
>0.85, waist >100 cm, numerous skin tags (achrochordons), and acanthosis nigricans[9]. Acanthosis 
nigricans is velvety, verrucous, hyperpigmented skin found most frequently on the back of the neck, 
axillae, and in other skin fold areas (see Fig. 1), and is a known indicator of underlying insulin resistance 
and decreased insulin sensitivity. Undiagnosed and untreated insulin resistance is linked to long-term 
sequelae, such as coronary artery disease, hyperlipidemia, and Type II diabetes[10]. 
 
FIGURE 1. 
Insulin Resistance/Hyperinsulinemia 
Hyperinsulinemia has been a known component of PCOS since at least 1984[11]. As obesity and body fat 
distribution have known effects on glucose metabolism, this contributes to the insulin resistance in HAIR-
AN[12,13] in obese women. Certainly not all women with HAIR-AN are obese, and when the above 
variables are controlled for, insulin resistance is still present[14,15]. In addition, obesity and PCOS have 
been found to have a synergistic effect on increasing insulin resistance[14,16]. As insulin resistance 
increases, pancreatic β cells increase insulin production to compensate. However, in women with HAIR-
AN, insulin response to glucose intake is attenuated[17] and defects in β cell function have been 
identified[18,19]. Genetic defects, such as mutations of the tyrosine kinase domain of the insulin receptor 
gene, have also been suggested in the pathogenesis of HAIR-AN[20,21]. 
Hyperandrogenism 
The prolonged, markedly elevated, insulin levels, which are associated with resistance and decreased 
sensitivity, may stimulate the ovary to generate androgens[1,20]. It is theorized that these high levels of 
insulin cross-react with insulin-like growth factors, therefore, directly stimulating the overproduction of 
ovarian androgens[1,10]. This gives rise to the hyperandrogenism associated with HAIR-AN. 
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Diagnosis 
There is no consistently used “gold standard” of diagnostic testing for HAIR-AN. Diagnosis is often based 
on the clinical findings, i.e., evidence of hyperandrogenism (acne, hirsutism) and evidence of insulin 
resitance (acanthosis nigricans)[5], but on the other hand, many women with insulin resistance do not have 
acanthosis nigricans[9,20]. Multiple laboratory tests have been posited as tools in the diagnosis of HAIR-
AN, including fasting insulin levels, fasting glucose-to-insulin ratio, glucose challenge testing, and the 
euglycemic hyperinsulinemic clamp. These lab values can be helpful; however, the only measure that is 
both sensitive and specific is the euglycemic hyperinsulinemic clamp. Regrettably, this test is both 
impractically complex and time consuming, and too expensive for the clinic setting[20]. Currently, there is 
no solid consensus as to what testing is most beneficial in the evaluation of patients with possible HAIR-
AN. 
Treatment 
Likewise, there is no consensus on the “standard of care” for the treatment of HAIR-AN syndrome. 
Traditional treatments have included weight loss, oral contraceptive pills, and antiandrogens. Debate 
continues regarding treatment with insulin-sensitizing agents, such as metformin.  
BMI is known to be directly proportional to insulin resistance[22]. Multiple studies have demonstrated 
that obese women with HAIR-AN can have decreased androgens and return of regular ovulation with 
weight loss[23,24,25]. As obesity has reached epidemic proportions in the U.S., achieving weight loss in 
patients, although not often easy, can have health benefits beyond those directly attributable to HAIR-AN. 
There is evidence that weight loss is more easily achieved after the hyperandrogenism and 
hyperinsulinemia have improved[26]. 
Oral contraceptive pills (OCP) are often used to improve menstrual cycle regularity, improve acne, and 
decrease hirsutism, and possess the added benefit of prevention of unintended pregnancy[27]. OCP may 
suppress the hypothalamic-pituitary-ovarian axis, therefore lowering ovarian steroid/androgen 
production[1]. There is no evidence that OCP improve insulin resistance or sensitivity. Some evidence 
suggests that OCP should not be used in patients with HAIR-AN, as they might decrease insulin 
sensitivity[28]. Recently, Yasmin® (Berlex), an OCP with drospirenone, a spironolactone analog, has been 
introduced that may be used in the treatment of the hyperandrogenism associated with HAIR-AN[29]. 
Antiandrogens, often in conjunction with OCP, may be utilized to decrease acne and hirsutism. These 
include spironolactone, GnRH agonists, and flutamide. Spironolactone frequently is used in conjunction 
with OCP to target hirsutism. Antiandrogens should not be used in sexually active women who are not on 
contraception, as they can have adverse fetal effects. 
Treatments aimed at directly increasing insulin sensitivity are the topic of much debate. Insulin 
sensitizers that are currently available in the U.S. include metformin, rosiglitazone, and pioglitazone 
(troglitazone is no longer available). Metformin is approved by the FDA for treatment of Type II diabetes 
mellitus (but not for insulin resistance), and in addition to enhancing peripheral glucose uptake, metformin 
increases insulin sensitivity. Metformin is the only insulin sensitizer that is approved for use in those 
patients 10–16 years old; however, recent data suggest that rosiglitazone may be beneficial in pediatric 
patients[30]. One of the most important clinical outcomes is the improvement in menstrual 
regularity/ovulation. Randomized, placebo-controlled trials of metformin and rosiglitazone in obese 
patients with PCOS have demonstrated ovulation rates of 30–42%[31,32,33]. In those with PCOS and 
severe insulin resistance, ovulation rates have reached 92%[34]. Insulin-sensitizing agents logically are 
more likely to induce ovulation in women with higher levels of insulin resistance[32,33,34]. Therefore, 
insulin-sensitizing agents are most useful for use in the HAIR-AN subset of PCOS.  
Insulin-sensitizing agents also improve hyperandrogenism. Metformin and pioglitazone have been 
shown to decrease serum androgens[31,35,36]. The decreased serum androgen levels are likely a direct 
consequence of decreased serum insulin levels. 
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Two small studies have been carried out in adolescents using metformin and dietary intervention. Both 
revealed weight loss and resumption of menses; however, the metformin effects were confounded by the 
dietary interventions[37,38]. In addition to the potential for metabolic acidosis and liver damage, 
metformin gives rise to gastrointestinal side effects which patients often dislike. 
CONCLUSIONS 
HAIR-AN syndrome is a disease that manifests in adolescence, yet may have long-reaching consequences 
into adulthood. It is important to recognize the symptoms as they present and to treat accordingly. 
Although HAIR-AN syndrome was first described over 30 years ago and many advances since been made, 
there are still areas which require continuing research: (1) continued insight into the genetic causes and 
their relationships with environmental influences, (2) continued development and evaluation of programs 
targeting the obesity epidemic, (3) development of more practical sensitive and specific laboratory 
diagnostic methods, (4) further investigation of treatment modalities, specifically of the insulin-sensitizing 
agents, (5) further investigation of the insulin-sensitizing agents in adolescent populations, and (6) studies 
evaluating long-term impact of treatment with insulin-sensitizing agents on the development of Type II 
diabetes and cardiovascular disease in patients with HAIR-AN. 
KEY POINTS 
• HAIR-AN is a subphenotype of polycystic ovary syndrome (PCOS), which differs by the presence 
of insulin resistance. 
• Acanthosis nigricans, acne, hirsutism, and menstrual irregularity should alert the provider to the 
possibility their patient has HAIR-AN. 
• Easily obtained laboratory values may assist with the diagnosis of HAIR-AN, but are not 
diagnostic in themselves. 
• Weight loss, oral contraceptive pills (OCP) use, and antiandrogens may be used in the treatment of 
HAIR-AN. 
• Insulin-sensitizing agents may also be used; however, their use is currently controversial based on 
potential side effects and lack of solid long-term data. 
REFERENCES 
1. Barbieri, R.L. and Ryan, K.J. (1983) Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome. A 
common endocrinopathy with distinct pathophysiologic features. Am. J. Obstet. Gynecol. 147, 90–101. 
2. Barbieri, R.L. (1994) Some genetic syndromes associated with hyperandrogenism. Contemp. Obstet. Gynecol. 39, 35–
48.  
3. Barbieri, R.L., Smith, S., and Ryan, K.J. (1988) The role of hyperinsulinism in the pathogenesis of ovarian 
hyperandrogenism. Fertil. Steril. 50, 197–212. 
4. Barbieri, R.L. and Hornstein, M.D. (1988) Hyperinsulinemia and ovarian hyperandrogenism. Endocrinol. Metab. 
Clin. North Am. 17, 685–703. 
5. Omar, H.A., Logsdon, S., and Richards, J. (2004) Clinical profiles, occurrence, and management of adolescent 
patients with HAIR-AN syndrome. TheScientificWorldJOURNAL 4, 507–511. 
6. Toscano, V., Balducci, R., Mangiantini, A., et al. (1998) Hyperandrogenism in the adolescent female. Steroids 63, 
308–313. 
7. Rosenfield, R.L., Ghai, K., Ehrmann, D.A., et al. (2000) Diagnosis of the polycystic ovary syndrome in adolescence; 
comparison of adolescent and adult hyperandrogenism. J. Pediatr. Endocrinol. Metab. 13S, 1285–1290. 
8. Ferriman, D. and Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. J. Clin. Endocrinol. 
Metab. 21, 1440–1447. 
9. Barbieri, R.L. (2000) Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am. J. 
Obstet. Gynecol. 183(6), 1412–1418. 
Rager and Omar: Androgen Excess Disorder  TheScientificWorldJOURNAL (2006) 6, 116–123
 
 120
10. Nestler, J.E. (1997) Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome , and its clinical 
implications. Semin. Reprod. Endocrinol. 15, 111–122. 
11. Dunaif, A., Graf, M., Mandel, J., et al. (1987) Characterization of groups of hyperandrogenic women with acanthosis 
nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J. Clin. Endocrinol. Metab. 65, 499–507. 
12. Yki-Jarvinen, H. and Koivisto, V.A. (1983) Effects of body composition on insulin sensitivity. Diabetes 32, 965–969. 
13. Bogardus, C., Lilioja, S., Mott, D., et al. (1985) Relationship between degree of obesity and in vivo insulin action in 
man. Am. J. Physiol. 248, E286–291. 
14. Dunaif, A., Segal, K.R., Shelley, D.R., et al. (1992) Evidence for distinctive and intrinsic defects in insulin action in 
polycystic ovary syndrome. Diabetes 41, 1257–1266. 
15. Morales, A.J., Laughlin, G.A., Butzow, T., et al. (1996) Insulin, somatotropic, and luteinizing hormones in lean and 
obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81, 2854–2864. 
16. Dunaif, A., Futterweit, W., Segal, K.R., et al. (1989) Profound peripheral insulin resistance, independent of obesity, in 
the polycystic ovary syndrome. Diabetes 38, 1165–1174. 
17. Dunaif, A. and Finegood, D.T. (1996) B cell dysfunction independent of obesity and glucose intolerance in the 
polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81, 947–952. 
18. O’Meara, N.M., Blackman, J.D., Ehrmann, D.A., et al. (1993) Defects in β cell function in functional ovarian 
hyperandrogenism. J. Clin. Endocrinol. Metab. 76, 1241–1247. 
19. Goodarzi, M.O., Erickson, S., Port, S., et al. (2005) β cell function: a key pathological determinant in polycystic ovary 
syndrome. J. Clin. Endocrinol. Metab. 90, 310–315. 
20. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for 
pathogenesis. Endocr. Rev. 18, 774–800. 
21. Globerman, H. (1998) Analysis of the insulin receptor gene tyrosine kinase domain in obese patients with 
hyperandrogenism, insulin resistance, and acanthosis nigricans. Int. J. Obes. Relat. Metab. Disord. 22, 349–353. 
22. Weyer, C., Bogardus, C., Mott, D.M., et al. (1999) The natural history of insulin secretory dysfunction and insulin 
resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104, 787–794. 
23. Bates, G.W. and Whitworth, N.S. (1982) Effect of body weight reduction on plasma androgens in obese infertile 
women. Fertil. Steril. 38, 406–409. 
24. Pasquali, R., Antenucci, D., Casimirri, F., et al. (1989) Clinical and hormonal characteristics of obese and 
amenorrheic women before and after weight loss. J. Clin. Endocrinol. Metab. 68, 173–179. 
25. Hollman, M., Runnebaum, B., and Gerhard, I. (1996) Effects of weight loss on the hormonal profile in obese infertile 
women. Hum. Reprod. 11, 1884–1891. 
26. Ibanez, L., Potau, N., and DeZegher, F. (1998) Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and 
the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J. Endocrinol. 
Invest. 32, 558–566. 
27. Jensen, J.T. and Speroff, L. (2000) Health benefits of oral contraceptives. Obstet. Gynecol. Clin. North Am. 27(4), 
705–707 . 
28. Diamanti-Kandarakis, E., Baillargeon, J.P., Iurno, M.J., et al. (2003) A modern medical quandary: polycystic ovary 
syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88, 1927–1932. 
29. Guido, M., Romualdi, D., Giuliani, M., et al. (2004) Drospirenone for the treatment of hirsute women with polycystic 
ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab. 89(6), 2817–2823. 
30. Tucker, M. (2005) Two oral agents benefit type 2 diabetes patients. Pediatr. News 39(7), 1. 
31. Nestler, J.E., Jakubowicz, D.J., Evans, W.S., et al. (1998) Effects of metformin on spontaneous and clomiphene-
induced ovulation in polycystic ovary syndrome. N. Engl. J. Med. 338, 1876–1880. 
32. Moghetti, P., Castello, R., Negri, C., et al. (2000) Metformin effects on clinical features, endocrine and metabolic 
profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 
month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 185, 139–146. 
33. Ghazeeri, G., Kutteh, W.H., Bryer-Ash, M., et al. (2003) Effect of rosiglitazone on spontaneous and clomiphene 
ctrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. 79, 562–566. 
34. Sepilian, V. and Nagamani, M. (2005) Effects of rosiglitazone in obese women with polycystic ovary syndrome and 
severe insulin resistance. J. Clin. Endocrinol. Metab. 90, 60–65. 
35. Nestler, J.E. and Jakubowicz, D.J. (1997) Lean women with polycystic ovary syndrome respond to insulin reduction 
with decreases in ovarian P450c17 activity alpha activity and serum androgens. J. Clin. Endocrinol. Metab. 82, 4075–
4079. 
36. Guido, M., Romualdi, D., Suriano, R., et al. (2004) Effect of pioglitazone treatment on the adrenal androgen response 
to corticotrophin in obese patients with polycystic ovary syndrome. Hum. Reprod. 19, 534–539. 
37. Gleuck, C.J. (2001) Metformin to restore normal menses in oligoamenorrheic teenage girls with polycystic ovary 
syndrome. J. Adolesc. Health 21, 160–116 . 
38. Kay, J.P. (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50, 
1457–1414. 
 
 
 
Rager and Omar: Androgen Excess Disorder  TheScientificWorldJOURNAL (2006) 6, 116–123
 
 121
This article should be cited as follows: 
Rager, K.M. and Omar, H.A. (2006) Androgen excess disorders in women: the severe insulin resistant hyperandrogenic 
syndrome, HAIR-AN. TheScientificWorldJOURNAL 6, 116–121. DOI 10.1100/tsw.2006.23. 
BIOSKETCHES 
Kristin M. Rager, MD, Assistant Professor, Section of Adolescent Medicine, Department of Pediatrics, 
University of Kentucky College of Medicine, Lexington. E-mail: Rager@uky.edu 
Hatim A. Omar, MD is Professor of Pediatrics and Obstetrics/Gynecology and Director of Adolescent 
Medicine and Young Parent programs at the Kentucky Clinic, University of Kentucky, Lexington. Dr. 
Omar has numerous publications in child health, adolescent health, medicine, obstetrics, and gynecology. 
E-mail: haomar2@uky.edu 
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
